NFDI4DS | UHH-SEMS - Publication Details

Wilfried Eberhardt

ORCID: 0000-0003-4284-3586

Publications

Citations

Views

---

Saved

---

About

Contact & Profiles

A5071766547

Research Areas

Lung Cancer Treatments and Mutations
Lung Cancer Diagnosis and Treatment
Lung Cancer Research Studies
Radiomics and Machine Learning in Medical Imaging
Cancer Immunotherapy and Biomarkers
Colorectal Cancer Treatments and Studies
Cancer Genomics and Diagnostics
Occupational and environmental lung diseases
Neuroendocrine Tumor Research Advances
Cancer Treatment and Pharmacology
Medical Imaging Techniques and Applications
Pleural and Pulmonary Diseases
Cancer therapeutics and mechanisms
Peptidase Inhibition and Analysis
Gastric Cancer Management and Outcomes
Medical Imaging and Pathology Studies
Hepatocellular Carcinoma Treatment and Prognosis
Melanoma and MAPK Pathways
HER2/EGFR in Cancer Research
Cancer Research and Treatments
Brain Metastases and Treatment
Head and Neck Cancer Studies
PI3K/AKT/mTOR signaling in cancer
Cancer Diagnosis and Treatment
Cholangiocarcinoma and Gallbladder Cancer Studies

Essen University Hospital
2016-2025

Ruhrlandklinik
2016-2025

University of Duisburg-Essen
2015-2024

Deutschen Konsortium für Translationale Krebsforschung
2023-2024

National Center for Tumor Diseases
2024

West Cancer Center
1999-2023

Keio University Hospital
2023

University of Chicago
2023

Memorial Sloan Kettering Cancer Center
2009-2023

Icahn School of Medicine at Mount Sinai
2023

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

OPENALEX - Publications

Julie R. Brahmer Karen L. Reckamp Paul Baas Lucio Crinó Wilfried Eberhardt and 20 more

Patients with advanced squamous-cell non-small-cell lung cancer (NSCLC) who have disease progression during or after first-line chemotherapy limited treatment options. This randomized, open-label, international, phase 3 study evaluated the efficacy and safety of nivolumab, a fully human IgG4 programmed death 1 (PD-1) immune-checkpoint-inhibitor antibody, as compared docetaxel in this patient population.We randomly assigned 272 patients to receive at dose mg per kilogram body weight every 2...

10.1056/nejmoa1504627 article EN New England Journal of Medicine 2015-05-31

The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer

OPENALEX - Publications

Peter Goldstraw Kari Chansky John Crowley Ramón Rami–Porta Hisao Asamura and 95 more

10.1016/j.jtho.2015.09.009 article EN publisher-specific-oa Journal of Thoracic Oncology 2016-01-01

Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial

OPENALEX - Publications

Robert Pirker Jose R. Pereira Aleksandra Szczęsna Joachim von Pawel Maciej Krzakowski and 13 more

10.1016/s0140-6736(09)60569-9 article EN The Lancet 2009-05-01

Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057)

OPENALEX - Publications

Leora Horn David R. Spigel Everett E. Vokes Esther Holgado Neal Ready and 24 more

Purpose Nivolumab, a programmed death-1 inhibitor, prolonged overall survival compared with docetaxel in two independent phase III studies previously treated patients advanced squamous (CheckMate 017; ClinicalTrials.gov identifier: NCT01642004) or nonsquamous 057; NCT01673867) non-small-cell lung cancer (NSCLC). We report updated results, including pooled analysis of the studies. Methods Patients stage IIIB/IV (N = 272) 582) NSCLC and disease progression during after prior platinum-based...

10.1200/jco.2017.74.3062 article EN Journal of Clinical Oncology 2017-10-12

EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study

OPENALEX - Publications

Robert Pirker Jose R. Pereira Joachim von Pawel Maciej Krzakowski Rodryg Ramlau and 9 more

10.1016/s1470-2045(11)70318-7 article EN The Lancet Oncology 2011-11-05

Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial

OPENALEX - Publications

Charles Butts Mark A. Socinski Paul Mitchell Nick Thatcher Libor Havel and 17 more

10.1016/s1470-2045(13)70510-2 article EN The Lancet Oncology 2013-12-09

Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non–Small-Cell Lung Cancer

OPENALEX - Publications

Hossein Borghaei Scott Gettinger Everett E. Vokes Laura Q.M. Chow Marco Angelo Burgio and 25 more

Immunotherapy has revolutionized the treatment of advanced non-small-cell lung cancer (NSCLC). In two phase III trials (CheckMate 017 and CheckMate 057), nivolumab showed an improvement in overall survival (OS) favorable safety versus docetaxel patients with previously treated, squamous nonsquamous NSCLC, respectively. We report 5-year pooled efficacy from these trials.Patients (N = 854; 017/057 pooled) ECOG PS ≤ 1, progression during or after first-line platinum-based chemotherapy were...

10.1200/jco.20.01605 article EN cc-by-nc-nd Journal of Clinical Oncology 2021-01-15

Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

OPENALEX - Publications

Johan Vansteenkiste Dirk De Ruysscher Wilfried Eberhardt Eric Lim Suresh Senan and 2 more

10.1093/annonc/mdt241 article EN publisher-specific-oa Annals of Oncology 2013-07-17

2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up

OPENALEX - Publications

Johan Vansteenkiste Lucio Crinó Christophe Dooms Jean-Yves Douillard C. Faivre‐Finn and 43 more

10.1093/annonc/mdu089 article EN publisher-specific-oa Annals of Oncology 2014-02-22

Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non–Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial

OPENALEX - Publications

Karen Kelly Nasser K. Altorki Wilfried Eberhardt Mary O’Brien David R. Spigel and 11 more

Purpose Epidermal growth factor receptor (EGFR) –tyrosine kinase inhibitors have proven efficacy in advanced non–small-cell lung cancer (NSCLC). We hypothesized that erlotinib would be efficacious the adjuvant setting. Patients and Methods An international randomized, double-blind, placebo-controlled study was conducted patients with completely resected IB to IIIA NSCLC whose tumors expressed EGFR protein by immunohistochemistry or amplification fluorescence situ hybridization. were assigned...

10.1200/jco.2015.61.8918 article EN Journal of Clinical Oncology 2015-09-01

Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial

OPENALEX - Publications

Roy S. Herbst Yan Sun Wilfried Eberhardt Paul Germonpré Nagahiro Saijo and 13 more

10.1016/s1470-2045(10)70132-7 article EN The Lancet Oncology 2010-06-08

The IASLC Lung Cancer Staging Project: External Validation of the Revision of the TNM Stage Groupings in the Eighth Edition of the TNM Classification of Lung Cancer

OPENALEX - Publications

Kari Chansky Frank Detterbeck Andrew G. Nicholson Valerie W. Rusch Eric Valliéres and 95 more

10.1016/j.jtho.2017.04.011 article EN publisher-specific-oa Journal of Thoracic Oncology 2017-04-28

The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for the Revision of the Clinical and Pathologic Staging of Small Cell Lung Cancer in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer

OPENALEX - Publications

Andrew G. Nicholson Kari Chansky John Crowley Ricardo Guijarro Kaoru Kubota and 95 more

10.1016/j.jtho.2015.10.008 article EN publisher-specific-oa Journal of Thoracic Oncology 2015-12-24

Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients With Resectable Stage IIIA(N2) and Selected IIIB Non–Small-Cell Lung Cancer After Induction Chemotherapy and Concurrent Chemoradiotherapy (ESPATUE)

OPENALEX - Publications

Wilfried Eberhardt Christoph Pöttgen Thomas Gauler Godehard Friedel Stefanie Veit and 17 more

Purpose Concurrent chemoradiotherapy with or without surgery are options for stage IIIA(N2) non–small-cell lung cancer. Our previous phase II study had shown the efficacy of induction chemotherapy followed by and in patients disease selected IIIB disease. Here, we compared definitive resectable III after induction. Patients Methods pathologically proven that medical/functional operability received chemotherapy, which consisted three cycles cisplatin 50 mg/m 2 on days 1 8 paclitaxel 175 day...

10.1200/jco.2015.62.6812 article EN Journal of Clinical Oncology 2015-11-03

Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer

OPENALEX - Publications

K.M. Kerr L. Bubendorf Martin J. Edelman Andrea Ascoli Marchetti Tony Mok and 40 more

10.1093/annonc/mdu145 article EN publisher-specific-oa Annals of Oncology 2014-04-10

The IASLC Lung Cancer Staging Project: Background Data and Proposed Criteria to Distinguish Separate Primary Lung Cancers from Metastatic Foci in Patients with Two Lung Tumors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer

OPENALEX - Publications

Frank C. Detterbeck Wilbur A. Franklin Andrew G. Nicholson Nicolas Girard Douglas A. Arenberg and 93 more

10.1016/j.jtho.2016.01.025 article EN publisher-specific-oa Journal of Thoracic Oncology 2016-03-02

2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease

OPENALEX - Publications

Benjamin Besse Alex A. Adjei Paul Baas Peter Meldgaard M. Nicolson and 42 more

10.1093/annonc/mdu123 article EN publisher-specific-oa Annals of Oncology 2014-03-26

The IASLC Lung Cancer Staging Project: Methodology and Validation Used in the Development of Proposals for Revision of the Stage Classification of NSCLC in the Forthcoming (Eighth) Edition of the TNM Classification of Lung Cancer

OPENALEX - Publications

Frank Detterbeck Kari Chansky Patti A. Groome Vanessa Bolejack John Crowley and 95 more

10.1016/j.jtho.2016.06.028 article EN publisher-specific-oa Journal of Thoracic Oncology 2016-07-22

The IASLC Lung Cancer Staging Project: Summary of Proposals for Revisions of the Classification of Lung Cancers with Multiple Pulmonary Sites of Involvement in the Forthcoming Eighth Edition of the TNM Classification

OPENALEX - Publications

Frank C. Detterbeck Andrew G. Nicholson Wilbur A. Franklin Edith M. Marom William D. Travis and 95 more

10.1016/j.jtho.2016.01.024 article EN publisher-specific-oa Journal of Thoracic Oncology 2016-03-03

The IASLC Mesothelioma Staging Project: Proposals for the M Descriptors and for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Mesothelioma

OPENALEX - Publications

Valerie W. Rusch Kari Chansky Hedy L. Kindler Anna K. Nowak Harvey I. Pass and 95 more

10.1016/j.jtho.2016.09.124 article EN publisher-specific-oa Journal of Thoracic Oncology 2016-09-30

Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial

OPENALEX - Publications

Lee M. Krug Hedy L. Kindler Hilary Calvert Christian Manegold Anne S. Tsao and 14 more

10.1016/s1470-2045(15)70056-2 article EN The Lancet Oncology 2015-03-29

The IASLC Lung Cancer Staging Project: Background Data and Proposals for the Application of TNM Staging Rules to Lung Cancer Presenting as Multiple Nodules with Ground Glass or Lepidic Features or a Pneumonic Type of Involvement in the Forthcoming Eighth Edition of the TNM Classification

OPENALEX - Publications

Frank Detterbeck Edith M. Marom Douglas A. Arenberg Wilbur A. Franklin Andrew G. Nicholson and 93 more

10.1016/j.jtho.2015.12.113 article EN publisher-specific-oa Journal of Thoracic Oncology 2016-03-03

Coming Soon ...